$1.52 (-1.30%)

Volume: 5.216M

Closed: Mar 21, 2023

Hollow Logo Score: -5.531
Esperion Therapeutics Stock
$1.52 (-1.30%)

Volume: 5.216M

Closed: Mar 21, 2023

Score Hollow Logo -5.531
NASDAQ:ESPR

Esperion Therapeutics Stock Company Profile

3891 Ranchero Drive, Suite 150

Ann Arbor MI 48108

734 887 3903

www.esperion.com


Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Click to get the best stock tips daily for free!

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a... ESPR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT